Hypothesis

Rare cells harboring high levels of mutant mitochondrial DNA release oxidized lipid‑rich extracellular vesicles that travel through the circulation and inhibit nuclear acetyl-CoA production in distant healthy cells, leading to reduced histone acetylation, epigenetic drift, and systemic aging phenotypes.

Mechanistic Rationale

• Mitochondrial dysfunction in mutant cells increases ROS generation, causing peroxidation of mitochondrial phospholipids and release of oxidized lipid species (e.g., 4‑HNE, oxLDL) into shed vesicles
• These vesicles are taken up by recipient cells where oxidized lipids inhibit ATP‑citrate lyase (ACLY) activity by forming covalent adducts on the enzyme’s active site, decreasing cytosolic acetyl-CoA synthesis from citrate
• Lower cytosolic acetyl-CoA limits the substrate pool for nuclear acetyl-CoA generation via ACLY or pyruvate dehydrogenase complex translocation, reducing nuclear acetyl‑CoA concentrations
• Depleted nuclear acetyl‑CoA diminishes histone acetyltransferase (p300/CBP) activity, causing global hypoacetylation of H3K9, H3K27 and H4K16, which correlates with transcriptional silencing of nuclear‑encoded mitochondrial genes and pro‑inflammatory pathways
• The resulting epigenetic state sustains a low‑grade inflammatory phenotype (inflammaging) that further stresses mitochondria, creating a feed‑forward loop

Novel Insight Beyond Current Models

While existing work emphasizes mitochondrial‑to‑nuclear signaling via metabolite flux, this hypothesis adds a vesicle‑mediated, intercultural transmission mechanism whereby a small subpopulation of mtDNA‑mutant cells exerts outsized influence by chemically modifying a key metabolic enzyme (ACLY) in recipient cells. It explains why bulk tissue shows low mutant load yet widespread acetyl‑CoA deficiency and epigenetic drift.

Testable Predictions

1. Vesicle Isolation – Ultracentrifugation of plasma from aged mice will yield vesicles enriched in oxidized lipids and mtDNA mutant signatures compared with young controls.
2. ACLY Inhibition – Treating young cultured fibroblasts with isolated aged‑mouse vesicles will decrease ACLY activity (measured by citrate‑to‑acetyl‑CoA conversion) and lower nuclear acetyl‑CoA levels (detected via mass spectrometry).
3. Epigenetic Consequence – Vesicle‑treated cells will show reduced H3K9ac and H3K27ac at promoters of nuclear‑encoded mitochondrial genes (e.g., Tfam, Cox5b) and increased expression of senescence markers (p16^INK4a^, SASP cytokines).
4. In Vivo Rescue – Genetic knockdown of ACLY in endothelial cells will exacerbate vesicle‑induced epigenetic changes, whereas pharmacological activation of ACLY (e.g., with SB‑204990) will restore nuclear acetyl‑CoA, histone acetylation, and improve grip strength and frailty indices in aged mice.
5. Causality of mtDNA Mutants – Mice harboring a mutator polymerase gamma allele (PoLG^mut/^) treated with an inhibitor of vesicle release (e.g., GW4869) will retain higher nuclear acetyl‑CoA levels and show delayed onset of age‑related phenotypes despite unchanged mtDNA mutation load.

Experimental Approach

• Step 1: Isolate plasma extracellular vesicles from young (3 mo) and aged (24 mo) WT and PoLG^mut/^ mice; characterize size, concentration, and oxidized lipid content (LC‑MS).
• Step 2: Apply vesicles to primary mouse hepatocytes; measure ACLY activity, cytosolic and nuclear acetyl‑CoA, and histone acetylation (Western blot, ELISA).
• Step 3: Perform RNA‑seq and ChIP‑seq for H3K9ac/H3K27ac to identify epigenetic changes.
• Step 4: In vivo, administer vesicles intravenously to young mice and monitor nuclear acetyl‑CoA (imaging‑based biosensor), histone acetylation, and frailty over 8 weeks.
• Step 5: Test rescue with ACLY activator or vesicle‑release inhibitor in aged PoLG^mut/^ mice; assess lifespan, metabolic health, and histopathological markers.

Potential Pitfalls and Controls

• Vesicle preparations may contain protein contaminants; use proteinase K treatment and lipid‑only controls to confirm lipid‑driven effects.
• Off‑target effects of ACLY activators; include inactive analog controls and verify target engagement via acetyl‑CoA measurements.
• Compensatory metabolic pathways (e.g., acetate salvage) could mask ACLY inhibition; measure acetate utilization and supplement with labeled acetate to trace nuclear acetyl‑CoA sources.

If validated, this hypothesis would shift focus from counting mtDNA mutations per cell to quantifying the secretory burden of mutant mitochondria, offering new therapeutic avenues that target vesicle release or lipid oxidation to preserve nuclear acetyl‑CoA–dependent epigenetics in aging.